This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Mar;18(3):230-231.

doi: 10.1016/S1474-4422(19)30022-5. Epub 2019 Feb 12.

The risk of PML from natalizumab - Authors' reply

Pei-Ran Ho¹, Nolan Campbell², Ih Chang²

Affiliations

PMID: 30784549
DOI: 10.1016/S1474-4422(19)30022-5

Comment

The risk of PML from natalizumab - Authors' reply

Pei-Ran Ho et al. Lancet Neurol. 2019 Mar.

. 2019 Mar;18(3):230-231.

doi: 10.1016/S1474-4422(19)30022-5. Epub 2019 Feb 12.

Authors

Pei-Ran Ho¹, Nolan Campbell², Ih Chang²

Affiliations

¹ Biogen, Cambridge, MA 02142, USA. Electronic address: peiran.ho@biogen.com.
² Biogen, Cambridge, MA 02142, USA.

PMID: 30784549
DOI: 10.1016/S1474-4422(19)30022-5

No abstract available

PubMed Disclaimer

Comment on

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Ho PR, et al. Lancet Neurol. 2017 Nov;16(11):925-933. doi: 10.1016/S1474-4422(17)30282-X. Epub 2017 Sep 29. Lancet Neurol. 2017. PMID: 28969984
The risk of PML from natalizumab.
Tugemann B. Tugemann B. Lancet Neurol. 2019 Mar;18(3):230. doi: 10.1016/S1474-4422(19)30021-3. Epub 2019 Feb 12. Lancet Neurol. 2019. PMID: 30784548 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information